Michael Sacerdote
Biotech

Ambit Biosciences: One-Trick Pony With A Broken Leg

Flush with $85 million in cash from its May 2013 IPO, armed with an outstanding scientific hypothesis, staffed by a world expert on leukemia, and nearly through with phase 2 clinical trials, Ambit Biosciences (AMBI) seems to be on the fast track to success. At the end of May, the esteemed private equity firm Orbimed purchased almost 1.5 million shares. The stock has nearly doubled to $13.52 since the beginning of July. Citigroup has given the company a rating of Outperform. Yet despite these excellent optics, careful review of the science and the economics indicates that common shareholders will almost certainly lose money, and probably all of it.

AMBI data by YCharts

Ambit currently has four drugs in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details